Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- FGF HBFG 2 Escherichia poly peptide proteo glycans neuro genesis
- Product Overview:
Fibroblast growth factor 2 (FGF2), also known as basic FGF (BFGF), is a signaling polypeptide and member of the FGF family that has roles in cell growth and differentiation.{54148,54149} Alternative translation produces multiple isoforms of FGF2: one 18 kDa low molecular weight isoform that is translated from a conventional AUG start codon and represents the core sequence common to all FGF2 isoforms, and several high molecular weight isoforms containing amino terminal extensions of the 18 kDa isoform that use CUG codons as alternative translational start sites.{54148} The 18 kDa isoform of FGF2 is found in the nucleus and cytoplasm and can be secreted by target cells. It forms a ternary complex with heparan sulfate proteoglycans and an FGF receptor (FGFR) at the cell surface resulting in activation of various signaling pathways, including Ras, Raf, MAPK, and ERK. High molecular weight isoforms are localized to the nucleus and induce signaling independent of FGFRs. FGF2 expression is spatially and temporally regulated during development and is concurrent with neurogenesis.{54150} Exogenous administration of FGF2 enhances neurogenesis in the subventricular zone and subgranular zone in an adult rat model of traumatic brain injury. It also reduces infarct size and increases myocardial capillary density in a canine model of myocardial infarction induced by permanent coronary artery occlusion.{54149} Lung and kidney expression of FGF2 is increased in a common marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.{54151} Cayman’s FGF2 (human, recombinant) protein can be used for cell-based assay applications. The protein consists of 147 amino acids and has a calculated molecular weight of 16.5 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.